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ABSTRACT 
Design of Experiments (DoE) is a statistical model that aims to determine if the factors under study affect the response, and if so, it determines 
the conditions under which this variable of interest can be optimized. In terms of pharmaceutical technology, independent variables are usually 
factors of the formulation, while dependent variables are properties of the product or parameters that indicate the performance of the process. 
Precisely, the dissolution test is a tool of interest for the developers of medicines since it allows them to evaluate the performance of a 
formulation designed in a solid pharmaceutical form, such as tablets. The present investigation used the design of experiments to establish and 
optimize the conditions of the dissolution test of a 10 mg Rupatadine fumarate tablets formulation, resulting in the use of HCl 0,1 N (pH 1) 
dissolution medium and a rotation speed of 100 rpm for the apparatus II USP, which allow the analysis of the product in a reproducible and 
reliable way. 
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INTRODUCTION 
Design of Experiments (DoE) is a concept used to organize, 
conduct and interpret the results of experiments in an 
efficient way, guaranteeing the collection of as much useful 
information as possible, through the execution of a small 
number of tests.1 
In general, the DoE is considered a multivariate analysis 
technique, which requires the establishment or definition 
of levels (values) of the analyzed factors as well as prior 
knowledge about the problem under study, either by 
experience or by research.2 
The main objective of an experimental study is to find the 
relationship between independent variables (factors) and 
dependent variables (results) that affect a certain process 
and its final product, according to a reference or 
workspace. An appropriate DoE can help to identify optimal 
conditions, critical material attributes (CMA), critical 
process parameters (CPP) and how these can affect critical 
quality attributes (CQA).1 
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The selection of an experimental design depends on the 
nature of the problem of interest, as well as the level of 
information that is wanted to obtain from it. In terms of 
pharmaceutical technology, independent variables are 
usually factors of formulation, while dependent variables 
are properties of the product or parameters that indicate 
the performance of the process. In the case of the 
development of pharmaceutical products, the DoE 
represents an excellent tool that allows to systematically 
manipulate factors according to a design prior to the 
establishment of specifications.1, 3 
A test that allows evaluating the performance in vitro of a 
formulation is the dissolution test. Precisely, this test is a 
requirement for any solid dosage form of oral 
administration and is well used in all phases of the 
development of a drug product in order to study the release 
of the active pharmaceutical ingredient, as well as the 
product stability. 4, 5 
In the early stages of the development, the dissolution test 
allows to guide the optimization of the release profile 
shown by the formulations. Likewise, this test is used as a 
quality control procedure for medicines, which allows the 
Research and Development department to detect the 
influence of critical variables that may be affecting the 
quality of the designed formulation.6   
The FDA guidance on dissolution testing for immediate 
release solid oral dosage forms, addresses the importance 
of using the Biopharmaceutical Classification System for the 
establishment of the dissolution test method to be 
performed, since this is based on the solubility and 
permeability of the active principle.4, 7 
For the present study, the dissolution test will be used as a 
performance parameter of a 10 mg Rupatadine Fumarate 
tablet formulation prototype. The raw material is an active 
pharmaceutical ingredient that constitutes a potent second 
generation antihistamine selective H1 receptor, so it is 
widely used in the symptomatic treatment of allergic 
rhinitis and urticaria in adults and children over 12 years, 
with a daily dose of 10 mg.8, 9 
The present research pretends to employ an optimization 
design in order to identify or find a combination of factors 
that correspond to an optimal response profile relative to 
the dissolution of the active pharmaceutical ingredient, that 
lets to establish the conditions of the test in such a way that 
the analysis can be done in a reproducible and reliable way. 
MATERIALS AND METHODS 
For the execution of this study it was decided to evaluate 
the performance of one formulation prototype shown in the 
table 1, regarding the dissolution test.  
 
Table 1: Qualitative composition of the formulation 
prototype 
Raw material 
Rupatadine Fumarate 
Monohydrate lactose 
Microcrystalline cellulose 
Sodium croscarmellose 
Magnesium stearate 
 
 
Equipment: 
HPLC: Thermo Scientific, model Ultimate 3000. 
Conditions: 
• Column: C18; 4.6 x 250 mm and pore size of 5 μm.  
• Mobile phase: 20% acetates buffer (pH 6) and 80% 
methanol.  
• Temperature: 35 ° C.  
• Injection volume: 20 μL.  
• Wavelength: 244 nm. 
Disolutor: Agilent Technologies, model 708-DS. 
Conditions: According to the sections “Preliminary study” 
and “Design of Experiments”. 
Methods 
Preliminary study:  
 Dissolution test: Six units of the formulation prototype, 
apparatus II USP (pallets), 75 rpm rotation speed, 
evaluating its performance in two dissolution 
mediums: One consisting of 900 mL of water and 
another by 900 mL of a phosphate buffer at pH 5, both 
at 37 ± 0.5ºC, for 30 minutes. 
 Chemical analysis: Samples were analyzed by the HPLC 
under the conditions established in the "Equipment" 
section. 
 Statistical analysis: An ANOVA was done to find out 
significant differences between the dissolution 
medium according the following: 
 Null hypothesis: The means are equal. 
 Alternative hypothesis: The means are different. 
 Level of significance: α = 0.05 
Design of Experiments:  
The DoE was done according the following: 
 Controlled variables: HPLC equipment and method of 
analysis, dissolutor, apparatus II USP (pallets), analyst, 
duration of the test (30 minutes), temperature of the 
dissolution medium (37.5 ± 0.5 °C), formulation to 
analyze, number of units per test (6 tablets), weight of 
the tablets (118-122 mg) and their hardness (5 - 6.5 
kp). 
 No controlled or noise variables: pH of the distilled 
water for the preparation of the mediums, 
environmental conditions, days of the tests. 
 Input variables or study factors and their respective 
levels: pH of the medium (1 and 5) and agitation speed 
(75 and 100 rpm). 
 Output variable or response: Average quantity of 
dissolved active pharmaceutical ingredient at 30 
minutes. 
 Type of design: Factorial design 22. 
 Repetitions: Six for each treatment. 
 Planning and organization of the experimental work: 
The dissolution tests were carried out according the 
design proposed in this section and the chemical 
analysis was done as established in the conditions of 
the HPLC equipment. 
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 Interpretation of the results: The statistical analysis of 
the results was carried out with the Minitab 17® 
program through a variance analysis (ANOVA) for the 
means of the factors studied (Ho: The means are the 
same, Ha: At least one of the means is significantly 
different), whose level of significance was 95% (α = 
0.05). We analyzed the factors and effects that 
significantly influenced the response variable (P value 
<0.05), as well as the interactions that were presented. 
The verification of the normality compliance, constant 
variance and independence of the residuals was 
carried out by using graphical methods. 
Table 2: Treatments for the proposed DoE. 
 
Treatment 
 
 
Medium pH  
 
Apparatus Speed (rpm) 
1 1 75 
2 1 100 
3 5 75 
4 5 100 
 
RESULTS 
Preliminary study 
The results obtained in the preliminary study allow to 
observe significant differences in the performance of the 
formulation in the dissolution test, when it was evaluated 
in a medium constituted by water and another by a buffer 
of phosphates, where the second one showed the highest 
percentages of dissolved amount at 30 minutes. 
Table 3. Results of the dissolution tests for the preliminary 
study. 
Medium 
 
Dissolved amount at 30 minutes / % 
1 2 3 4 5 6 
Water 82,0 81,2 81,0 80,7 86,2 87,2 
Buffer 95,1 95,9 102,5 90,6 99,0 99,5 
 
Tabla 4: ANOVA one way for the exploratory study of the dissolution medium. 
Source DF Adj SS Adj MS F value P value 
Medium 1 592,2 592,21 46,41 0,000 
Error 10 127,6 12,76   
Total 11 719,8    
 
Figure 1: Comparison between the dissolved amount of the active pharmaceutical ingredient in terms of percentage, in the 
preliminary dissolution study. 
 
Figure 2: Residual plots for disolved percentage in the 
preliminary study. 
Design of Experiments 
Regarding the results obtained through the DoE, it was 
observed that the dissolution medium is a critical variable to 
be considered in the test, where the use of a HCl 0.1 N (pH 1) 
allows to obtain the highest dissolution percentages. On the 
other hand, the speed of the dissolution apparatus does not 
constitute a factor that shows significant differences 
between the two speeds studied. However, the interaction 
between the two factors is of great interest since certain 
combinations result in higher dissolution percentages.  
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Table 5: DoE execution. 
Std 
Order 
Run 
Order 
Rotation 
speed 
(rpm) 
pH 
Dissolved 
% at 30 
minutes 
11 1 75 5,0 95,1 
3 2 75 5,0 95,9 
4 3 100 5,0 95,3 
21 4 75 1,0 102,4 
24 5 100 5,0 100,5 
19 6 75 5,0 102,5 
2 7 100 1,0 101,3 
8 8 100 5,0 94,3 
13 9 75 1,0 101,8 
22 10 100 1,0 108,6 
17 11 75 1,0 99,0 
10 12 100 1,0 105,9 
7 13 75 5,0 90,6 
15 14 75 5,0 99,0 
18 15 100 1,0 104,3 
12 16 100 5,0 96,2 
9 17 75 1,0 98,0 
5 18 75 1,0 96,5 
6 19 100 1,0 101,0 
20 20 100 5,0 95,8 
1 21 75 1,0 98,8 
14 22 100 1,0 99,8 
16 23 100 5,0 96,0 
23 24 75 5,0 99,5 
 
 
Table 6: One Way ANOVA for the DoE. 
Source DF Adj SS Adj MS 
F-
Value 
P-
Value 
Model 3 185,25 61,752 6,43 
0,003 
 
Linear 2 150,45 75,227 7,83 0,003 
Rotation 
speed 
1 16,50 16,500 1,72 0,205 
Medium pH 1 133,95 133,954 13,95 0,001 
2-Way 
interaction 
(Medium pH 
* Rotation 
speed) 
1 34,80 34,800 3,62 0,071 
Error 20 192,03 9,602   
Total 23 377,29    
 
 
Figure 3: Residual plots for the DoE. 
 
 
Figure 4: Pareto diagram for the analysis of standardized 
effects. 
 
 
Figure 5: Diagram of interactions between the study factors. 
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Figure 6: Main effects diagram. 
 
Figure 7: Geometric representation of the factorial design 22. 
DISCUSSION 
When carrying out the dissolution test initially in water, it 
was possible to observe that the data did not provide a 
reliability of the method of analysis, since there were 
anomalous situations in terms of the dissolved quantity of 
the active pharmaceutical ingredient as a function of time. 
In a study consulted about the dissolution of Rupatadine 
Fumarate tablets, the test was executed for 30 minutes in a 
medium consisting of 900 mL of water and another by 900 
mL of an acetate buffer (pH 4.5), at 37.0 ± 0.5 ° C, using the 
apparatus II at 75 rpm. This study revealed large differences 
in the performance of the formulation in both media, since in 
water it showed dissolution percentages around 80% and in 
the buffer the values were under 70%.10 
Although the matrix of the formulation presented in that 
study differs with the proposed in the present investigation, 
it was observed that the performance of our formulation in 
water was even poorer than in the reference study, so it was 
decided to compare such parameter in this medium, with the 
one of another constituted by a phosphate buffer at pH 5 as 
an exploratory study.  
It was then necessary to determine between both mediums, 
which one was suitable to be taken into consideration for the 
execution of the DoE. Figure 1 shows the performance of the 
tablets of the proposed formulation in the two mediums. In 
addition, it should be noted that distilled water as a medium 
represents a factor that can´t be controlled at all, due to the 
variability of its pH. 
When performing the analysis of variances between these 
two mediums, the p-value turned out to be lower than the 
level of significance (0.01 <0.05), so the alternative 
hypothesis is accepted, which implies that there are 
significant differences between the water and buffer as a 
dissolution medium. Also, as can be seen in Figure 2, 
compliance of the normality, equality of variances and 
independence of the respective residues is checked for the 
ANOVA in question.  
From the results of the preliminary study, and unlike the 
reference one, it was determined that the phosphate buffer 
does constitute a medium in which it is possible to obtain a 
good performance of the proposed formulation in the 
dissolution test. 
However, taking into consideration the above, the same 
reference study also carried out dissolution tests in a 
medium constituted by 900 mL of 0.1 N HCl, which obtained 
the best results. That behave is logical due to the fact that the 
active pharmaceutical ingredient is an acid salt or weak base 
salt.8, 10, 11   
Thus, since our formulation didn´t show a good dissolution 
in water, it was then decided to execute the DoE using 
mediums constituted by phosphate buffer pH 5 and by HCl 
0.1 N of pH 1, to evaluate the performance of the proposed 
formulation in the dissolution test. 
The mentioned above is due to the fact that both mediums 
provide suitable sink conditions for the execution of the test, 
in such a way that they allow to reliably evaluate the 
performance of the formulation of interest.11 
The general objective of the design of experiments 
performed is not far from the universal, which lies in 
improving the response, being in this case the average of the 
dissolved amount of drug at 30 minutes. 12  
All those variables that had to be controlled during the tests 
were defined, as well as the identification of the factors in 
which that was not possible or commonly referred to as 
noise variables; where in addition to the pH of the distilled 
water, stand out the environmental conditions. 
However, noise variables were minimized thanks to the 
randomization of the analysis of the samples, as can be seen 
in Table 5, where there were a standard order and an order 
of analysis. The above allowed distributing the error 
attributable to those factors, among all the results.1, 12 
Therefore, the only two variables that remained to be 
analyzed were the already defined pH of the medium (1 and 
5) and, in addition, the speed of the dissolution apparatus 
(75 and 100 rpm). Working with a 22 factorial design made 
the treatment of the data more manageable, analyzing only 
four treatments with six repetitions each as established in 
the dissolution test, for a total of 24 samples.  
With the implementation of the proposed experimental 
design, its ANOVA indicates that there are no significant 
differences between the speeds used in the test, since the p-
value is greater than the level of significance (0.205> 0.05).  
However, for the pH of the medium it is established that 
there are differences between HCl 0.1 N (pH 1) and the 
phosphate buffer (pH 5), because the p value corresponds to 
0.003 which is lower than the established level of 
significance. 
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Likewise, it is important to mention that the interaction 
between the two factors could be significant as long as a 
level of significance of 90% (α = 0.1) or close to 92% (α = 
0.08) is established. 
The Pareto diagram that can be observed in figure 4, allows 
to determine the magnitude and importance of the 
standardized effects, which are the changes observed in the 
response variable due to a change of level in the factors. 
In this case only the respective bar for the pH of the medium 
manages to overcome the reference line. Therefore only that 
factor is statistically significant at the level of α = 0.05 
according to the terms of the established model.13 
Figure 6 is the graphic representation of the main effects, 
where it is possible to observe the levels of the factors on the 
horizontal axis and in the vertical one there is located the 
average of the response observed according to each level. In 
this case, the main effect of the pH of the medium is greater 
than the one of the speed, because the difference between 
the means of its two levels is greater.12 
In figure 5, it can be seen that when the speed increases from 
75 rpm to 100 rpm, the average of the dissolved amount 
decreases slightly at pH 5. Whereas, if there is such an 
increase in speed when the test is carried out in a medium at 
pH 1, the mean of the dissolved amount increases markedly.  
This implies that if it is desired to maximize, minimize or 
bring the response to a target value, the speed level can´t be 
changed without taking into account the level of the pH of 
the medium. Based on this interpretation, it can be assumed 
that there is an interaction between the factors. However, as 
mentioned above, such interaction is not significant for the 
level of significance initially established.  
Precisely, one of the main uses of an interaction chart lies in 
the contribution made in the selection of the optimal 
condition for the operation of a particular process and the 
consequent improvement in its performance. 
In addition to the above, it is also possible to make this 
determination through a geometric representation. In the 22 
factorial design, each vertex of a square is considered as a 
design or treatment point. The area bounded by this square 
is known as the experimental region and, in principle, the 
conclusions obtained from the experiment only have validity 
in this region.12, 13  
If Figure 7 is analyzed, it is possible to determine that the 
treatment which combines a medium with pH 1 at a speed of 
100 rpm gives the higher percentages of drug dissolved 
(103.48 %), while the worst of the treatments integrates a 
medium with pH 5 and a speed of 100 rpm (96,35 %).  
Finally, as a requirement for any analysis of variance, it is 
necessary to do a verification of the assumptions of 
normality, equality of variances and independence of 
residuals. 
Figure 3 is representative of a sample of residues that have a 
normal distribution (p value 0.701 ˃ 0.05). Also, this figure 
allows to check the independence of the residuals, since the 
represented points do not follow a specific pattern and also 
allows satisfying the constant variance assumption, because 
the points are distributed in a random way on the horizontal 
band.1, 13 
CONCLUSIONS 
The preliminary study allowed discarding water as a 
medium of dissolution since the performance of the tablets 
of the formulation under study did not prove to be adequate. 
On the other hand, the phosphate buffer turned out to be a 
medium in which the tablets showed an acceptable 
performance.  
However, the experimental design carried out determined 
that the medium of dissolution constituted a factor that 
significantly affected the response variable, which is, the 
average percentage of active pharmaceutical ingredient 
dissolved at 30 minutes, whereas the apparatus rotation 
speed does not represent a significant impact on the 
response studied. Thus, it was shown that better results 
were obtained at higher speeds in the ideal medium.  
Therefore, the present study allowed to optimize the 
performance of the formulation in the dissolution test, by 
providing the appropriate tools for the establishment of the 
ideal analysis method, which consists of a medium 
constituted by 900 mL of HCl 0.1 N, at 37.5 ± 0.5 ° C, 
apparatus II and at a speed of 100 rpm. 
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